Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is a report on a Patient Forum jointly hosted by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the ESRC-funded Biomodifying technologies project. The Forum was hosted in January 2020. The report details the purpose of the forum, and reports on the topics of the forum: the potential clinical applications of 'biomodifying technologies' such as gene editing, 3D bioprinting and induced pluripotent stem cells, issues of risk and uncertainty, personalised or customised treatments, and long-term follow up care for patients treated with these novel medicines. The report also details the discussions with forum participants, who included independent patent representatives, representatives of patient organisations and charities, and members of different departments within the MHRA.

Original publication

DOI

10.5281/zenodo.5243793

Type

Other

Publication Date

24/08/2022

Keywords

Stem cells, gene editing, bioprinting, additive manufacturing, MHRA, public engagement, patient forum